Picton Mahoney Asset Management’s Jasper Therapeutics JSPR Stock Holding History

Picton Mahoney Asset Management’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-9,994	Closed	-$993K	–	921
2021 Q2	$993K	Sell	9,994 -27,506	-73%	-$2.73M	0.03%	539
2021 Q1	$3.72M	Hold	37,500	–	–	0.18%	162
2020 Q4	$3.75M	Hold	37,500	–	–	0.18%	151
2020 Q3	$3.72M	Hold	37,500	–	–	0.21%	140
2020 Q2	$3.8M	Hold	37,500	–	–	0.22%	130
2020 Q1	$3.6M	Buy	+37,500	New	+$3.67M	0.2%	110

Other funds holding JSPR

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPARFS

Leverage Partners Absolute Return Fund SPC Cayman Islands Ky1-11111, Cayman Islands $54K AUM

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Picton Mahoney Asset Management's JSPR Position: Q3 2021 in Review

Picton Mahoney Asset Management sold out of Jasper Therapeutics (JSPR) in Q3 2021, closing a stake of 9,994 shares — an estimated $993K sold.

Picton Mahoney Asset Management first reported a position in JSPR in Q1 2020 and held it in 6 quarters. The position peaked at $3.8M in Q2 2020. 10 funds tracked by Wall St. Rank hold JSPR as of Q3 2021.

Picton Mahoney Asset Management reported no remaining Jasper Therapeutics position as of Q3 2021 after selling out during the quarter.
Picton Mahoney Asset Management sold 9,994 Jasper Therapeutics shares in Q3 2021, an estimated $993K.
Picton Mahoney Asset Management first reported a position in Jasper Therapeutics in Q1 2020 and held it in 6 quarters.
Picton Mahoney Asset Management's Jasper Therapeutics position peaked at $3.8M in Q2 2020.
10 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2021.

Based on Picton Mahoney Asset Management's 13F filing for Q3 2021, filed 9 Nov 2021.